TrialSignal transduction and targeted therapy2025

Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.

Ning Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.